Literature DB >> 25465110

Osteosclerosis induced by denosumab.

Eisuke Kobayashi1, Nokitaka Setsu2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25465110     DOI： 10.1016/S0140-6736(14)61338-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Integration of denosumab therapy in the management of giant cell tumors of bone.

Authors:  Daniel T Miles; Ryan T Voskuil; Wood Dale; Joel L Mayerson; Thomas J Scharschmidt
Journal:  J Orthop       Date:  2020-03-28

Review 2.  Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.

Authors:  Yujuan Zhang; Diana Milojevic
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

3.  Severe hypercalcemia following denosumab treatment in a juvenile patient.

Authors:  Nokitaka Setsu; Eisuke Kobayashi; Naofumi Asano; Naoko Yasui; Hiroshi Kawamoto; Akira Kawai; Keisuke Horiuchi
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

Review 4.  Denosumab: an Emerging Therapy in Pediatric Bone Disorders.

Authors:  Alison M Boyce
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

5.  Denosumab and surgery for the treatment of Perthes' disease in a 9-year-old boy: favorable course documented by comprehensive imaging- a case report.

Authors:  A Ludwig Meiss; Florian Barvencik; Kornelia Babin; Gerald Eggers-Stroeder
Journal:  Acta Orthop       Date:  2017-03-14       Impact factor: 3.717

6.  Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor.

Authors:  Daisuke Kajiwara; Hiroto Kamoda; Tsukasa Yonemoto; Shintaro Iwata; Takeshi Ishii; Toshinori Tsukanishi; Seiji Ohtori; Masashi Yamazaki; Akihiko Okawa
Journal:  Asian Spine J       Date:  2016-06-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.